Expertise in
127
conditions

Dr. Jing X. Li

Radiation Oncology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Offers Telehealth
Expertise in
127
conditions
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 

Overview

Jing Li is a Radiation Oncologist in Houston, Texas. Dr. Li is highly rated in 127 conditions, according to our data. Her top areas of expertise are Breast Cancer, Lung Cancer, Osteosarcoma, Endoscopy, and Percutaneous Coronary Intervention (PCI).

Her clinical research consists of co-authoring 17616 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial
Enrollment Status: Completed
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drugs: Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin
Study Phase: Phase 4
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Biological, Other, Radiation, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement
A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Other, Radiation, Procedure
Study Phase: Phase 2
A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery vs. Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases
A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery vs. Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases
A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2
Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis
Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Radiation, Other
Study Phase: Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Sitravatinib, Tislelizumab
Study Phase: Phase 1/Phase 2
The Multi-center Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV) in Chinese Han Adults (CAR-PWV Study）
The Multi-center Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV) in Chinese Han Adults (CAR-PWV Study）
Enrollment Status: Unknown
Publish Date: May 29, 2020
Intervention Type: Radiation
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Enrollment Status: Completed
Publish Date: February 04, 2019
Intervention Type: Procedure
A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday
A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday
Enrollment Status: Unknown
Publish Date: July 13, 2017
Intervention Type: Drug
Study Drug: Amifostine
Study Phase: Phase 2
View 11 Less Clinical Trials

17532 Total Publications

Signal pathway and active compounds of Penicillium griseofulvum against triple-negative breast cancer.
Signal pathway and active compounds of Penicillium griseofulvum against triple-negative breast cancer.
Journal: Journal of Asian natural products research
Published: January 23, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Bouthaina S. Dabaja
Radiation Oncology | Oncology | Radiology
Expertise in
21
conditions
Dr. Bouthaina S. Dabaja
Radiation Oncology | Oncology | Radiology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Bouthaina Dabaja is a Radiation Oncologist and an Oncologist in Houston, Texas. Dr. Dabaja is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Mycosis Fungoides.

Anuja Jhingran
Expertise in
8
conditions
Dr. Anuja Jhingran
Radiation Oncology
Expertise in
8
conditions
Dr. Anuja Jhingran
Radiation Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Anuja Jhingran is a Radiation Oncologist in Houston, Texas. Dr. Jhingran is highly rated in 8 conditions, according to our data. Her top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Endometrial Cancer, and Vaginal Cancer.

Expertise in
18
conditions
Dr. Gary B. Gunn
Radiation Oncology | Radiology
Expertise in
18
conditions
Dr. Gary B. Gunn
Radiation Oncology | Radiology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Gary Gunn is a Radiation Oncologist and a Radiologist in Houston, Texas. Dr. Gunn is highly rated in 18 conditions, according to our data. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Adenoid Cystic Carcinoma, Gastrostomy, and Thyroidectomy.

Frequently Asked Questions about Dr. Jing X. Li

How do I make an appointment with Dr. Jing X. Li?

You can book an appointment with Dr. Jing X. Li by calling their office at 713-592-5433. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jing X. Li a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jing X. Li is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jing X. Li specialize in?

While Dr. Jing X. Li is a Radiation Oncology, they have specific expertise in Breast Cancer, Lung Cancer, and Osteosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Jing X. Li participate in research or clinical trials?

Yes. Dr. Jing X. Li has published 17532 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Jing X. Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jing X. Li accept my insurance?

Dr. Jing X. Li accepts most major insurance plans, including Humana. We recommend calling the office directly at 713-592-5433 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
View All 14 Elite Conditions
View All 48 Distinguished Conditions
View All 65 Advanced Conditions
View All 82 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile